{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T22:39:44Z","timestamp":1789684784773,"version":"4.0.1"},"reference-count":60,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaad.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.jaad.2025.09.028","type":"journal-article","created":{"date-parts":[[2025,9,16]],"date-time":"2025-09-16T11:50:01Z","timestamp":1758023401000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Low-dose naltrexone for treatment of dermatologic conditions: A clinical review"],"prefix":"10.1016","author":[{"given":"Maggie H.","family":"Zhou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk M.","family":"Elston","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian W.","family":"Morrison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5913-9304","authenticated-orcid":false,"given":"Shari R.","family":"Lipner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaad.2025.09.028_bib1","first-page":"219","article-title":"Naltrexone extended-release injection: an option for the management of opioid abuse","volume":"2","author":"Taylor","year":"2011","journal-title":"Subst Abuse Rehabil"},{"issue":"2","key":"10.1016\/j.jaad.2025.09.028_bib2","doi-asserted-by":"crossref","first-page":"159","DOI":"10.5021\/ad.2016.28.2.159","article-title":"Clinical efficacy and safety of naltrexone combination therapy in older patients with severe pruritus","volume":"28","author":"Lee","year":"2016","journal-title":"Ann Dermatol"},{"key":"10.1016\/j.jaad.2025.09.028_bib3","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.jdcr.2021.11.036","article-title":"The importance of dosage for naltrexone treatment in Hailey-Hailey disease","volume":"23","author":"Grolleau","year":"2022","journal-title":"JAAD Case Rep"},{"key":"10.1016\/j.jaad.2025.09.028_bib4","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1146\/annurev-med-062613-093100","article-title":"Opioid receptors","volume":"67","author":"Stein","year":"2016","journal-title":"Annu Rev Med"},{"issue":"5","key":"10.1016\/j.jaad.2025.09.028_bib5","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1111\/j.1600-0625.2009.00844.x","article-title":"Opioids and the skin--where do we stand?","volume":"18","author":"Bigliardi","year":"2009","journal-title":"Exp Dermatol"},{"issue":"12","key":"10.1016\/j.jaad.2025.09.028_bib6","doi-asserted-by":"crossref","first-page":"1900","DOI":"10.1111\/exd.14669","article-title":"Role of kappa-opioid and mu-opioid receptors in pruritus: peripheral and central itch circuits","volume":"31","author":"Kim","year":"2022","journal-title":"Exp Dermatol"},{"issue":"8","key":"10.1016\/j.jaad.2025.09.028_bib7","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1111\/1346-8138.15407","article-title":"Non-neuronal kappa-opioid receptor activation enhances epidermal keratinocyte proliferation, and modulates mast cell functions in human skin ex vivo","volume":"47","author":"Ch\u00e9ret","year":"2020","journal-title":"J Dermatol"},{"issue":"2","key":"10.1016\/j.jaad.2025.09.028_bib8","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1111\/bph.12687","article-title":"Activation of the \u03b4-opioid receptor promotes cutaneous wound healing by affecting keratinocyte intercellular adhesion and migration","volume":"172","author":"Bigliardi","year":"2015","journal-title":"Br J Pharmacol"},{"issue":"3","key":"10.1016\/j.jaad.2025.09.028_bib9","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.bcp.2015.06.016","article-title":"Duration of opioid receptor blockade determines biotherapeutic response","volume":"97","author":"McLaughlin","year":"2015","journal-title":"Biochem Pharmacol"},{"issue":"4","key":"10.1016\/j.jaad.2025.09.028_bib10","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1111\/pan.15070","article-title":"Low-dose naltrexone for pediatric chronic pain and inflammatory states: perioperative considerations","volume":"35","author":"Huang","year":"2025","journal-title":"Paediatr Anaesth"},{"issue":"8","key":"10.1016\/j.jaad.2025.09.028_bib11","doi-asserted-by":"crossref","DOI":"10.5070\/D3258045142","article-title":"Low-dose naltrexone: a novel adjunctive treatment in symptomatic alopecias?","volume":"25","author":"Tortelly","year":"2019","journal-title":"Dermatol Online J"},{"issue":"2","key":"10.1016\/j.jaad.2025.09.028_bib12","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/0165-3806(86)90025-8","article-title":"Opioid antagonist-induced modulation of cerebral and hippocampal development: histological and morphometric studies","volume":"393","author":"Zagon","year":"1986","journal-title":"Brain Res"},{"issue":"2","key":"10.1016\/j.jaad.2025.09.028_bib13","doi-asserted-by":"crossref","first-page":"793","DOI":"10.3892\/ijo.2016.3567","article-title":"Naltrexone at low doses upregulates a unique gene expression not seen with normal doses: implications for its use in cancer therapy","volume":"49","author":"Liu","year":"2016","journal-title":"Int J Oncol"},{"issue":"9","key":"10.1016\/j.jaad.2025.09.028_bib14","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/j.jdcr.2019.06.022","article-title":"Hailey-Hailey disease treated successfully with naltrexone and magnesium","volume":"5","author":"Alajmi","year":"2019","journal-title":"JAAD Case Rep"},{"issue":"3","key":"10.1016\/j.jaad.2025.09.028_bib15","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1001\/jamadermatol.2017.5463","article-title":"Variable response to naltrexone in patients with Hailey-Hailey disease","volume":"154","author":"Cao","year":"2018","journal-title":"JAMA Dermatol"},{"issue":"5","key":"10.1016\/j.jaad.2025.09.028_bib16","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1111\/bjd.16045","article-title":"Low-dose naltrexone: a novel treatment for Hailey-Hailey disease","volume":"178","author":"Campbell","year":"2018","journal-title":"Br J Dermatol"},{"issue":"10","key":"10.1016\/j.jaad.2025.09.028_bib17","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1001\/jamadermatol.2017.2445","article-title":"Low-dose naltrexone treatment of familial benign pemphigus (Hailey-Hailey disease)","volume":"153","author":"Ibrahim","year":"2017","journal-title":"JAMA Dermatol"},{"issue":"7","key":"10.1016\/j.jaad.2025.09.028_bib18","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1016\/j.jdcr.2018.07.002","article-title":"Generalized familial benign chronic pemphigus (Hailey-Hailey disease) treated successfully with low-dose naltrexone","volume":"4","author":"Kollman","year":"2018","journal-title":"JAAD Case Rep"},{"issue":"3","key":"10.1016\/j.jaad.2025.09.028_bib19","doi-asserted-by":"crossref","DOI":"10.1111\/dth.12892","article-title":"Use of low-dose naltrexone in the treatment of severe Hailey-Hailey disease: one case report","volume":"32","author":"Garayar Cantero","year":"2019","journal-title":"Dermatol Ther"},{"issue":"5","key":"10.1016\/j.jaad.2025.09.028_bib20","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1007\/s00404-020-05705-0","article-title":"Vulvar Hailey-Hailey disease treated with low-dose naltrexone: case report and literature review","volume":"302","author":"Sousa Gomes","year":"2020","journal-title":"Arch Gynecol Obstet"},{"issue":"11","key":"10.1016\/j.jaad.2025.09.028_bib21","first-page":"19","article-title":"Recalcitrant Hailey-Hailey disease successfully treated with low-dose naltrexone","volume":"13","author":"Michael","year":"2020","journal-title":"J Clin Aesthet Dermatol"},{"issue":"6","key":"10.1016\/j.jaad.2025.09.028_bib22","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1111\/bjd.18861","article-title":"Improvement of Hailey-Hailey disease with low-dose naltrexone","volume":"182","author":"Jasans-Barcel\u00f3","year":"2020","journal-title":"Br J Dermatol"},{"issue":"2","key":"10.1016\/j.jaad.2025.09.028_bib23","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1016\/j.jaad.2019.04.024","article-title":"Low-dose naltrexone therapy in benign chronic pemphigus (Hailey-Hailey disease): a case series","volume":"81","author":"Riquelme-Mc Loughlin","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2025.09.028_bib24","article-title":"Improvement in Hailey-Hailey disease with a combination of low-dose naltrexone and oral magnesium chloride: a case report","volume":"8","author":"Lim","year":"2020","journal-title":"SAGE Open Med Case Rep"},{"issue":"5","key":"10.1016\/j.jaad.2025.09.028_bib25","doi-asserted-by":"crossref","first-page":"567","DOI":"10.4103\/idoj.IDOJ_453_18","article-title":"Low-dose naltrexone-induced remission in Hailey-Hailey disease maintained in remission with topical combination of ketamine and diphenhydramine","volume":"10","author":"Sonthalia","year":"2019","journal-title":"Indian Dermatol Online J"},{"issue":"6","key":"10.1016\/j.jaad.2025.09.028_bib26","article-title":"Treatment of recalcitrant Hailey-Hailey disease with naltrexone and dupilumab: a report of two cases","volume":"16","author":"Santoso","year":"2024","journal-title":"Cureus"},{"issue":"1","key":"10.1016\/j.jaad.2025.09.028_bib27","article-title":"Combination of naltrexone and isotretinoin for the treatment of Darier disease","volume":"15","author":"Costa","year":"2023","journal-title":"Cureus"},{"issue":"5","key":"10.1016\/j.jaad.2025.09.028_bib28","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1111\/jdv.15457","article-title":"Variable response to low-dose naltrexone in patients with Darier disease: a case series","volume":"33","author":"Boehmer","year":"2019","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jaad.2025.09.028_bib29","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.jdcr.2023.06.012","article-title":"Low-dose naltrexone as treatment for epidermolysis bullosa pruriginosa-associated refractory pruritus","volume":"38","author":"LaMonica","year":"2023","journal-title":"JAAD Case Rep"},{"issue":"11","key":"10.1016\/j.jaad.2025.09.028_bib30","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2021-243773","article-title":"Prurigo excori\u00e9e treated with low dose naltrexone","volume":"14","author":"Timoney","year":"2021","journal-title":"BMJ Case Rep"},{"key":"10.1016\/j.jaad.2025.09.028_bib31","doi-asserted-by":"crossref","DOI":"10.1155\/2011\/804296","article-title":"Low-dose naltrexone for pruritus in systemic sclerosis","volume":"2011","author":"Frech","year":"2011","journal-title":"Int J Rheumatol"},{"key":"10.1016\/j.jaad.2025.09.028_bib32","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1111\/j.1749-6632.1999.tb08705.x","article-title":"Effective treatment of pruritus with naltrexone, an orally active opiate antagonist","volume":"885","author":"Metze","year":"1999","journal-title":"Ann N Y Acad Sci"},{"issue":"5","key":"10.1016\/j.jaad.2025.09.028_bib33","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/j.jaad.2018.02.010","article-title":"Lichen planus and lichenoid dermatoses: clinical overview and molecular basis","volume":"79","author":"Tziotzios","year":"2018","journal-title":"J Am Acad Dermatol"},{"issue":"8","key":"10.1016\/j.jaad.2025.09.028_bib34","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1007\/s00403-024-03360-y","article-title":"Oral naltrexone in the treatment of lichen planopilaris and frontal fibrosing alopecia","volume":"316","author":"Perez","year":"2024","journal-title":"Arch Dermatol Res"},{"issue":"1","key":"10.1016\/j.jaad.2025.09.028_bib35","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.jaad.2024.03.010","article-title":"Attenuation of disease process following treatment with low-dose naltrexone in patients with frontal fibrosing alopecia and lichen planopilaris: a retrospective study","volume":"91","author":"Yossef","year":"2024","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"10.1016\/j.jaad.2025.09.028_bib36","article-title":"Oral low-dose naltrexone in the treatment of frontal fibrosing alopecia and lichen planopilaris: an uncontrolled open-label prospective study","volume":"15","author":"Hamel","year":"2023","journal-title":"Cureus"},{"issue":"2","key":"10.1016\/j.jaad.2025.09.028_bib37","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1080\/09546634.2020.1774488","article-title":"The efficacy and safety of oral low dose naltrexone versus placebo in the patients with lichen planopilaris: a randomized controlled clinical trial","volume":"33","author":"Lajevardi","year":"2022","journal-title":"J Dermatolog Treat"},{"issue":"12","key":"10.1016\/j.jaad.2025.09.028_bib38","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1001\/jamadermatol.2024.4098","article-title":"Low-dose naltrexone use in biopsy-proven lichen planus of the nails","volume":"160","author":"Bray","year":"2024","journal-title":"JAMA Dermatol"},{"issue":"4","key":"10.1016\/j.jaad.2025.09.028_bib39","first-page":"270","article-title":"Compounded low-dose naltrexone for the treatment of guttate psoriasis: a case report","volume":"22","author":"Muller","year":"2018","journal-title":"Int J Pharm Compd"},{"issue":"1","key":"10.1016\/j.jaad.2025.09.028_bib40","article-title":"Low-dose naltrexone: an alternative treatment for erythrodermic psoriasis","volume":"11","author":"Beltran Monasterio","year":"2019","journal-title":"Cureus"},{"issue":"6","key":"10.1016\/j.jaad.2025.09.028_bib41","doi-asserted-by":"crossref","first-page":"579","DOI":"10.29271\/jcpsp.2020.06.579","article-title":"Efficacy of low dose naltrexone in psoriasis","volume":"30","author":"Khan","year":"2020","journal-title":"J Coll Physicians Surg Pak"},{"issue":"6","key":"10.1016\/j.jaad.2025.09.028_bib42","doi-asserted-by":"crossref","DOI":"10.1111\/dth.12720","article-title":"Successful treatment of dermatomyositis with low-dose naltrexone","volume":"31","author":"Tran","year":"2018","journal-title":"Dermatol Ther"},{"issue":"4","key":"10.1016\/j.jaad.2025.09.028_bib43","first-page":"271","article-title":"Combination therapy of oral LDN and topical pentoxifylline, rifampin, clindamycin for hidradenitis suppurativa","volume":"28","author":"Bertrand","year":"2024","journal-title":"Int J Pharm Compd"},{"issue":"3","key":"10.1016\/j.jaad.2025.09.028_bib44","article-title":"Low-dose naltrexone for excoriation disorder","volume":"16","author":"Varghese","year":"2024","journal-title":"Cureus"},{"issue":"10","key":"10.1016\/j.jaad.2025.09.028_bib45","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1001\/jamadermatol.2017.2446","article-title":"Treatment of Hailey-Hailey disease with low-dose naltrexone","volume":"153","author":"Albers","year":"2017","journal-title":"JAMA Dermatol"},{"issue":"4","key":"10.1016\/j.jaad.2025.09.028_bib46","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1159\/000077841","article-title":"A comparative study on the effects of naltrexone and loratadine on uremic pruritus","volume":"208","author":"Legroux-Crespel","year":"2004","journal-title":"Dermatology"},{"issue":"5","key":"10.1016\/j.jaad.2025.09.028_bib47","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1177\/120347540500900502","article-title":"Successful treatment of refractory aquagenic pruritus with naltrexone","volume":"9","author":"Ingber","year":"2005","journal-title":"J Cutan Med Surg"},{"issue":"7","key":"10.1016\/j.jaad.2025.09.028_bib48","article-title":"Safety of naltrexone in patients with cirrhosis","volume":"6","author":"Thompson","year":"2024","journal-title":"JHEP Rep"},{"issue":"3","key":"10.1016\/j.jaad.2025.09.028_bib49","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1111\/j.1525-1470.2008.00699.x","article-title":"The use of naltrexone in the management of severe generalized pruritus in biliary atresia: report of a case","volume":"25","author":"Chang","year":"2008","journal-title":"Pediatr Dermatol"},{"issue":"9","key":"10.1016\/j.jaad.2025.09.028_bib50","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1089\/cap.2019.0056","article-title":"Naltrexone reduces binge eating and purging in adolescents in an eating disorder program","volume":"29","author":"Stancil","year":"2019","journal-title":"J Child Adolesc Psychopharmacol"},{"issue":"6","key":"10.1016\/j.jaad.2025.09.028_bib51","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1097\/ADM.0000000000001342","article-title":"Diagnosis and treatment of presumed naltrexone-XR-precipitated opioid withdrawal in a patient chronically treated with buprenorphine-XR: a case report","volume":"18","author":"Moore","year":"2024","journal-title":"J Addict Med"},{"key":"10.1016\/j.jaad.2025.09.028_bib52","series-title":"Incorporating alcohol pharmacotherapies into medical practice","first-page":"27","article-title":"Chapter 4\u2014oral naltrexone","year":"2009"},{"issue":"6","key":"10.1016\/j.jaad.2025.09.028_bib53","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1016\/j.jaad.2018.12.031","article-title":"The uses of naltrexone in dermatologic conditions","volume":"80","author":"Lee","year":"2019","journal-title":"J Am Acad Dermatol"},{"issue":"11","key":"10.1016\/j.jaad.2025.09.028_bib54","first-page":"1140","article-title":"Novel treatment using low-dose naltrexone for lichen planopilaris","volume":"16","author":"Strazzulla","year":"2017","journal-title":"J Drugs Dermatol"},{"issue":"4","key":"10.1016\/j.jaad.2025.09.028_bib55","doi-asserted-by":"crossref","first-page":"321","DOI":"10.5055\/jom.2011.0073","article-title":"Analgesic efficacy of intravenous naloxone for the treatment of postoperative pruritus: a meta-analysis","volume":"7","author":"Murphy","year":"2018","journal-title":"J Opioid Manag"},{"issue":"4","key":"10.1016\/j.jaad.2025.09.028_bib56","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000028653","article-title":"Low dose naloxone for pruritus in systemic sclerosis: case series and literature review","volume":"101","author":"Meridor","year":"2022","journal-title":"Medicine"},{"key":"10.1016\/j.jaad.2025.09.028_bib57","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2024.1298928","article-title":"Deciphering the immunological interactions: targeting preeclampsia with Hydroxychloroquine's biological mechanisms","volume":"15","author":"Gaji\u0107","year":"2024","journal-title":"Front Pharmacol"},{"issue":"4","key":"10.1016\/j.jaad.2025.09.028_bib58","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1177\/12034754231188323","article-title":"Treatment patterns for hydroxychloroquine, methotrexate, and mycophenolate mofetil in lichen planopilaris: a retrospective chart review","volume":"27","author":"Williams","year":"2023","journal-title":"J Cutan Med Surg"},{"issue":"4","key":"10.1016\/j.jaad.2025.09.028_bib59","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1097\/LGT.0000000000000843","article-title":"Hydroxychloroquine for vulval lichen planus","volume":"28","author":"Thompson","year":"2024","journal-title":"J Low Genit Tract Dis"},{"issue":"5","key":"10.1016\/j.jaad.2025.09.028_bib60","doi-asserted-by":"crossref","first-page":"3126","DOI":"10.1111\/odi.14746","article-title":"Hydroxychloroquine is effective in oral lichen planus: a multicenter, randomized, controlled trial","volume":"30","author":"Xie","year":"2024","journal-title":"Oral Dis"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962225028129?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962225028129?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,7]],"date-time":"2025-12-07T18:59:15Z","timestamp":1765133955000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0190962225028129"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":60,"alternative-id":["S0190962225028129"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2025.09.028","relation":{},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Low-dose naltrexone for treatment of dermatologic conditions: A clinical review","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2025.09.028","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 by the American Academy of Dermatology, Inc.","name":"copyright","label":"Copyright"}]}}